Literature DB >> 18414713

The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004.

Robert P Myers1, MingFu Liu, Abdel Aziz Shaheen.   

Abstract

BACKGROUND: Nearly 1% of Canadians are infected with the hepatitis C virus (HCV). Simulation analyses have suggested that HCV will place an increasing burden on the health care system as the infected population ages, but supportive clinical data are limited.
OBJECTIVES: To study temporal trends in HCV-related hospitalizations and predictors of increased health care utilization from a Canadian population-based perspective.
METHODS: An administrative hospitalization database from the Calgary Health Region was used to identify patients who were admitted for HCV between 1994 and 2004. The primary outcomes were liver-related HCV hospitalizations, length of stay, hospital costs and in-hospital mortality. Average annual growth rates in outcomes were calculated and subgroup analyses were conducted according to age, sex and HIV/HCV coinfection status.
RESULTS: Between 1994 and 2004, there were 4002 HCV-related hospitalizations; 22% were liver-related. Liver-related hospitalizations, lengths of stay and in-hospital mortality increased approximately fourfold or an average of 15% to 18% annually (P<0.0005). Patients aged 40 to 59 years and HIV/HCV coinfected patients experienced the largest average annual growth rates (19% to 27% and 30% to 40%, respectively; P<0.0005), reflecting the accelerated natural history of HCV in these subgroups. Hospital costs for liver-related HCV hospitalizations increased by an average of 41% annually (P=0.001) between 2000 and 2004. The average annual increase in liver-related hospitalizations remained significant in a sensitivity analysis, even when 75% of HCV cases were under-reported in 1994.
CONCLUSIONS: The present studies' findings confirm the growing burden of HCV on the Canadian health care system. Strategies to prevent HCV infection and maximize the dissemination and most effective use of potentially curative antiviral therapies are necessary to reduce these trends.

Entities:  

Mesh:

Year:  2008        PMID: 18414713      PMCID: PMC2662896          DOI: 10.1155/2008/173153

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  35 in total

1.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

2.  Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Authors:  H Yoshida; Y Shiratori; M Moriyama; Y Arakawa; T Ide; M Sata; O Inoue; M Yano; M Tanaka; S Fujiyama; S Nishiguchi; T Kuroki; F Imazeki; O Yokosuka; S Kinoyama; G Yamada; M Omata
Journal:  Ann Intern Med       Date:  1999-08-03       Impact factor: 25.391

3.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

Authors:  María Buti; Ramón San Miguel; Max Brosa; Juan M Cabasés; Montserrat Medina; Miguel Angel Casado; Leslie Fosbrook; Rafael Esteban
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

5.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  Trends in health care resource use for hepatitis C virus infection in the United States.

Authors:  William C Grant; Ravi R Jhaveri; John G McHutchison; Kevin A Schulman; Teresa L Kauf
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

Review 7.  Natural history of hepatitis C.

Authors:  David L Thomas; Leonard B Seeff
Journal:  Clin Liver Dis       Date:  2005-08       Impact factor: 6.126

8.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

9.  Hepatitis C: a sleeping giant?

Authors:  M J Alter
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  30 in total

1.  Pay now or pay (more) later: tracking the costs of hepatitis C infection.

Authors:  Robert P Myers; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2010-12       Impact factor: 3.522

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants: a census-linked population-based cohort study.

Authors:  Edward Ng; Robert P Myers; Doug Manuel; Claudia Sanmartin
Journal:  CMAJ Open       Date:  2016-04-28

4.  Rate, delay and predictors of hepatitis C treatment in British Columbia.

Authors:  Alan Hoi Lun Yau; Terry Lee; Alnoor Ramji; Hin Hin Ko
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

Review 5.  Protease inhibitors for hepatitis C: economic implications.

Authors:  Stuart J Turner; Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

6.  Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.

Authors:  Ramsey Cheung; Ajitha Mannalithara; Gurkirpal Singh
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

7.  Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study.

Authors:  Robert P Myers; Pam Crotty; Susanna Town; Janine English; Kevin Fonseca; Raymond Tellier; Mark G Swain; S Elizabeth McGregor; Steven J Heitman; Robert J Hilsden
Journal:  CMAJ Open       Date:  2015-01-13

8.  The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Authors:  Hemant Shah; Marc Bilodeau; Kelly W Burak; Curtis Cooper; Marina Klein; Alnoor Ramji; Dan Smyth; Jordan J Feld
Journal:  CMAJ       Date:  2018-06-04       Impact factor: 8.262

9.  An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Hemant Shah; Kelly W Burak; Curtis Cooper; Jordan J Feld
Journal:  Can J Gastroenterol Hepatol       Date:  2015-01-13

10.  Cost-effectiveness of screening for hepatitis C in Canada.

Authors:  William W L Wong; Hong-Anh Tu; Jordan J Feld; Tom Wong; Murray Krahn
Journal:  CMAJ       Date:  2015-01-12       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.